Trending Now
Sorrento Therapeutics Inc. (NASDAQ: SRNE) Commences Phase 2 Study Enrolment Evaluating...
Sorrento Therapeutics Inc. (NASDAQ: SRNE) has announced the commencement of enrolment in its second phase efficacy trial of human allogeneic adipose-derived mesenchymal stem cells...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Oragenics, Inc (NYSE: OGEN) Surges 34% Amidst Webinar Announcement and Intranasal...
Oragenics, Inc. (NYSE: OGEN) has recently garnered significant attention with a notable increase in its stock price. As of 3:38 PM EDT,...
MAKE IT MODERN
LATEST REVIEWS
Insmed (NASDAQ: INMD) Shares Surge as New Drug Shows Promise
Insmed Incorporated (NASDAQ: INSM) witnessed a dramatic surge in its stock price following the release of promising results from its latest drug...
MAKE IT MODERN
PERFORMANCE TRAINING
S&P 500 heading for another major correction
U.S. stock futures are red to start the day. This should be an interesting week for the markets as we are coming...
1606 Corp (CBDW) Expands into Artificial Intelligence with the Introduction of CHATCBDW
The realm of artificial intelligence has been present for a while, yet it garnered heightened attention with the launch of ChatGPT and...
Dan Staner Of Moderna Inc (NASDAQ: MRNA) Says Covid Vaccine Will Be Delivered In...
Moderna Inc (NASDAQ: MRNA)’s European Head, Dan Staner, said the company would roll out covid vaccine in early Q3 2021 than previously planned.
Expects to...
Agenus Inc (NASDAQ: AGEN) Inks Licensing Deal With Bristol-Myers Squibb Co (NYSE: BMY) To...
Agenus Inc (NASDAQ: AGEN) has partnered with Bristol-Myers Squibb Co (NYSE: BMY). As part of the agreement, Bristol Myers Squibb Co will study an...
Selecta Biosciences Inc (NASDAQ:SELB) Will Advance Gene Therapy Program In H1 2021 In MMA:...
Selecta Biosciences Inc (NASDAQ:SELB) posts a loss of $24.1 million in Q2 2020. Its general and administrative expenses in Q2 2020 are $5.6 million,...
MAKE IT MODERN
